2.22 USD
-0.1 (-4.31%)
BTMD gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of BTMD get a neutral evaluation. Nothing too spectacular is happening here. BTMD is valued quite cheap, while showing a decent growth score. This is a good combination!
1. Profitability
1.1 Basic Checks
- BTMD had positive earnings in the past year.
- BTMD had a positive operating cash flow in the past year.
- Of the past 5 years BTMD 4 years were profitable.
- Of the past 5 years BTMD 4 years had a positive operating cash flow.
1.2 Ratios
- BTMD has a better Return On Assets (25.87%) than 98.43% of its industry peers.
- BTMD's Return On Invested Capital of 45.22% is amongst the best of the industry. BTMD outperforms 99.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.87% | ||
| ROE | N/A | ||
| ROIC | 45.22% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Profit Margin, with a value of 14.72%, BTMD belongs to the top of the industry, outperforming 86.91% of the companies in the same industry.
- BTMD's Profit Margin has declined in the last couple of years.
- BTMD has a better Operating Margin (16.09%) than 85.86% of its industry peers.
- BTMD's Operating Margin has declined in the last couple of years.
- BTMD has a Gross Margin of 72.23%. This is in the better half of the industry: BTMD outperforms 79.06% of its industry peers.
- In the last couple of years the Gross Margin of BTMD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.09% | ||
| PM (TTM) | 14.72% | ||
| GM | 72.23% |
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
2. Health
2.1 Basic Checks
- BTMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- BTMD has less shares outstanding than it did 1 year ago.
- Compared to 1 year ago, BTMD has a worse debt to assets ratio.
2.2 Solvency
- An Altman-Z score of 2.24 indicates that BTMD is not a great score, but indicates only limited risk for bankruptcy at the moment.
- The Altman-Z score of BTMD (2.24) is comparable to the rest of the industry.
- BTMD has a debt to FCF ratio of 4.18. This is a neutral value as BTMD would need 4.18 years to pay back of all of its debts.
- Looking at the Debt to FCF ratio, with a value of 4.18, BTMD belongs to the top of the industry, outperforming 84.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.18 | ||
| Altman-Z | 2.24 |
ROIC/WACC4.86
WACC9.31%
2.3 Liquidity
- A Current Ratio of 1.01 indicates that BTMD should not have too much problems paying its short term obligations.
- BTMD has a worse Current ratio (1.01) than 84.29% of its industry peers.
- BTMD has a Quick Ratio of 1.01. This is a bad value and indicates that BTMD is not financially healthy enough and could expect problems in meeting its short term obligations.
- BTMD has a Quick ratio of 0.72. This is amonst the worse of the industry: BTMD underperforms 85.34% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.01 | ||
| Quick Ratio | 0.72 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 190.00% over the past year.
- The earnings per share for BTMD have been decreasing by -48.53% on average. This is quite bad
- Looking at the last year, BTMD shows a very negative growth in Revenue. The Revenue has decreased by -18.44% in the last year.
- BTMD shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.38% yearly.
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
Revenue 1Y (TTM)-18.44%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.67%
3.2 Future
- The Earnings Per Share is expected to grow by 41.42% on average over the next years. This is a very strong growth
- Based on estimates for the next years, BTMD will show a small growth in Revenue. The Revenue will grow by 6.89% on average per year.
EPS Next Y229.18%
EPS Next 2Y9.09%
EPS Next 3Y9.09%
EPS Next 5Y41.42%
Revenue Next Year-3.44%
Revenue Next 2Y-0.37%
Revenue Next 3Y2.36%
Revenue Next 5Y6.89%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- With a Price/Earnings ratio of 2.55, the valuation of BTMD can be described as very cheap.
- BTMD's Price/Earnings ratio is rather cheap when compared to the industry. BTMD is cheaper than 97.91% of the companies in the same industry.
- BTMD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.38.
- The Price/Forward Earnings ratio is 8.48, which indicates a very decent valuation of BTMD.
- Based on the Price/Forward Earnings ratio, BTMD is valued cheaply inside the industry as 90.05% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.29, BTMD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.55 | ||
| Fwd PE | 8.48 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, BTMD is valued cheaply inside the industry as 94.24% of the companies are valued more expensively.
- BTMD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. BTMD is cheaper than 98.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 2.95 | ||
| EV/EBITDA | 6.27 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The decent profitability rating of BTMD may justify a higher PE ratio.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y9.09%
EPS Next 3Y9.09%
5. Dividend
5.1 Amount
- BTMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:BTMD (1/20/2026, 2:35:56 PM)
2.22
-0.1 (-4.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-10 2026-03-10/amc
Inst Owners63.14%
Inst Owner Change-0.53%
Ins Owners10.06%
Ins Owner Change0%
Market Cap101.37M
Revenue(TTM)195.65M
Net Income(TTM)28.79M
Analysts81.82
Price Target4.94 (122.52%)
Short Float %4.31%
Short Ratio8.06
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)270.4%
Min EPS beat(2)178.65%
Max EPS beat(2)362.15%
EPS beat(4)3
Avg EPS beat(4)249.23%
Min EPS beat(4)-1.96%
Max EPS beat(4)458.07%
EPS beat(8)5
Avg EPS beat(8)105.05%
EPS beat(12)7
Avg EPS beat(12)16.44%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.43%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)-1.55%
Revenue beat(4)1
Avg Revenue beat(4)-1.97%
Min Revenue beat(4)-4.66%
Max Revenue beat(4)1.66%
Revenue beat(8)2
Avg Revenue beat(8)-1.65%
Revenue beat(12)4
Avg Revenue beat(12)-1.32%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.91%
PT rev (3m)-10.36%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.77%
EPS NY rev (1m)0%
EPS NY rev (3m)23.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.82%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 2.55 | ||
| Fwd PE | 8.48 | ||
| P/S | 0.52 | ||
| P/FCF | 2.95 | ||
| P/OCF | 2.53 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.27 |
EPS(TTM)0.87
EY39.19%
EPS(NY)0.26
Fwd EY11.79%
FCF(TTM)0.75
FCFY33.95%
OCF(TTM)0.88
OCFY39.45%
SpS4.28
BVpS-1.59
TBVpS-1.9
PEG (NY)0.01
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 25.87% | ||
| ROE | N/A | ||
| ROCE | 57.24% | ||
| ROIC | 45.22% | ||
| ROICexc | 92.24% | ||
| ROICexgc | 190.38% | ||
| OM | 16.09% | ||
| PM (TTM) | 14.72% | ||
| GM | 72.23% | ||
| FCFM | 17.59% |
ROA(3y)1.27%
ROA(5y)30.69%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y-32.05%
ROICexgc growth 5YN/A
ROICexc growth 3Y-33.38%
ROICexc growth 5YN/A
OM growth 3Y-13.56%
OM growth 5Y-5.58%
PM growth 3Y-59.09%
PM growth 5Y-39.26%
GM growth 3Y2.76%
GM growth 5Y3.16%
F-Score7
Asset Turnover1.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 4.18 | ||
| Debt/EBITDA | 3.02 | ||
| Cap/Depr | 144.67% | ||
| Cap/Sales | 2.85% | ||
| Interest Coverage | 3.81 | ||
| Cash Conversion | 113.15% | ||
| Profit Quality | 119.51% | ||
| Current Ratio | 1.01 | ||
| Quick Ratio | 0.72 | ||
| Altman-Z | 2.24 |
F-Score7
WACC9.31%
ROIC/WACC4.86
Cap/Depr(3y)122.96%
Cap/Depr(5y)152.59%
Cap/Sales(3y)2.04%
Cap/Sales(5y)2.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)190%
EPS 3Y-71.33%
EPS 5Y-48.53%
EPS Q2Q%-33.33%
EPS Next Y229.18%
EPS Next 2Y9.09%
EPS Next 3Y9.09%
EPS Next 5Y41.42%
Revenue 1Y (TTM)-18.44%
Revenue growth 3Y12.26%
Revenue growth 5Y12.38%
Sales Q2Q%-6.67%
Revenue Next Year-3.44%
Revenue Next 2Y-0.37%
Revenue Next 3Y2.36%
Revenue Next 5Y6.89%
EBIT growth 1Y-29.68%
EBIT growth 3Y-2.97%
EBIT growth 5Y6.11%
EBIT Next Year30.98%
EBIT Next 3Y13.56%
EBIT Next 5Y13.39%
FCF growth 1Y43.63%
FCF growth 3Y8.58%
FCF growth 5Y10.09%
OCF growth 1Y53.94%
OCF growth 3Y10.29%
OCF growth 5Y12.28%
BIOTE CORP -A / BTMD FAQ
Can you provide the ChartMill fundamental rating for BIOTE CORP -A?
ChartMill assigns a fundamental rating of 5 / 10 to BTMD.
Can you provide the valuation status for BIOTE CORP -A?
ChartMill assigns a valuation rating of 9 / 10 to BIOTE CORP -A (BTMD). This can be considered as Undervalued.
Can you provide the profitability details for BIOTE CORP -A?
BIOTE CORP -A (BTMD) has a profitability rating of 6 / 10.
How financially healthy is BIOTE CORP -A?
The financial health rating of BIOTE CORP -A (BTMD) is 4 / 10.
How sustainable is the dividend of BIOTE CORP -A (BTMD) stock?
The dividend rating of BIOTE CORP -A (BTMD) is 0 / 10 and the dividend payout ratio is 0%.